(Total Views: 212)
Posted On: 02/24/2019 8:31:38 AM
Post# of 154687
Yes, love to hear first patient with TNBC injected or mono pivotal news tomorrow. The pr also said a business update, giving the timing and words in the pr, I first thought partner, until comments NP made the next day, but who knows. I’m looking forward to this cc, probably more than any before.
With the 8 cancer indications all at once, I assume that also spreads an extremely wide net with potential partners. Kind of a shot across the bow to the BPs in cancer.
“will host an investment community conference call to provide a business update, including current licensing opportunities, as well as the recently announced multi-pathway approach to concurrently explore leronlimab’s ability to block CCR5 in its role for potentially 8 cancer indications.”
With the 8 cancer indications all at once, I assume that also spreads an extremely wide net with potential partners. Kind of a shot across the bow to the BPs in cancer.
“will host an investment community conference call to provide a business update, including current licensing opportunities, as well as the recently announced multi-pathway approach to concurrently explore leronlimab’s ability to block CCR5 in its role for potentially 8 cancer indications.”
(0)
(0)
